Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Oxford BioMedica plc
DescriptionHumanized mAb against oncofetal antigen 5T4
Molecular Target Oncofetal antigen 5T4
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation
PartnerPfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today